Key result
Carperitide and furosemide similarly decreased left atrial pressure from baseline (14.75 mmHg) to 10.24 mmHg and 10.77 mmHg, respectively, in dogs with experimentally induced mitral regurgitation.
Why the study?
Does carperitide reduce left atrial pressure and neurohumoral activation compared to furosemide in dogs with experimentally induced mitral regurgitation?
RCT (n=6)
randomized, cross-over
Does carperitide reduce left atrial pressure and neurohumoral activation compared to furosemide in dogs with experimentally induced mitral regurgitation?
Absolute Event Rate: 10.24% vs 10.77%
In a canine model of acute mitral regurgitation, carperitide reduced left atrial pressure similarly to furosemide but with significantly less neurohumoral activation.
Suggests carperitide as furosemide alternative in experimental canine MR; leaves open clinical translation and neurohumoral effects.
BACKGROUND: The effects of carperitide on left atrial pressure (LAP) in dogs with mitral valve disease (mitral regurgitation, MR) have not been documented. OBJECTIVE: The objective was to compare the short-term effects of carperitide versus furosemide on LAP and neurohumoral factors in MR dogs. ANIMALS: Six healthy Beagle dogs weighing 9.8-12.6 kg (2 males and 4 females; aged 3 years) were used. METHODS: Experimental, randomized, cross-over, and interventional study. Carperitide 0.1 μg/kg/min or furosemide 0.17 mg/kg/h (1 mg/kg/6 h) was administered to dogs with surgically induced MR for 6 hours, and after a 14 day wash-out period, the other drug was administered. LAP, plasma renin activity, plasma aldosterone, and echocardiographic variables were measured. RESULTS: Left atrial pressure was decreased similarly after the administration of carperitide 0.1 μg/kg/min and furosemide 0.17 mg/kg/h (1 mg/kg/6 h) compared with baseline in dogs with MR (Baseline 14.75 ± 3.74 mmHg, carperitide 10.24 ± 4.97 mmHg, P < .01, furosemide 10.77 ± 5.06 mmHg, P < .05). Plasma renin activity and plasma aldosterone were significantly lower after the administration of carperitide than after the administration of furosemide (P < .05, respectively). CONCLUSIONS AND CLINICAL IMPORTANCE: Carperitide significantly decreased LAP in dogs with acute MR caused by experimental chordal rupture. Carperitide can have additional benefits from the viewpoint of minimal activation of neurohumoral factors in the treatment of dogs with MR. Additional studies in dogs with spontaneous disease are warranted.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2013) conducted an RCT in mitral valve regurgitation (n=6). Carperitide vs. Furosemide 0.17 mg/kg/h was evaluated on Left atrial pressure. Carperitide and furosemide similarly decreased left atrial pressure from baseline (14.75 mmHg) to 10.24 mmHg and 10.77 mmHg, respectively, in dogs with experimentally induced mitral regurgitation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: